AcquisitionOther
Chiesi Group acquired KalVista Pharmaceuticals
Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.
Deal tape row
Chiesi Group -> KalVista Pharmaceuticals · approximately $1.9 billion
To acquire the first oral, on-demand therapy for hereditary angioedema (EKTERLY) and strengthen Chiesi's rare immunology portfolio.
Open source record (SEC) ↗